Scapho 150 mg contains Secukinumab (Secukinumab Injection), a fully human monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a cytokine involved in inflammatory and autoimmune diseases. By inhibiting IL-17A, Secukinumab helps control inflammation, reduce skin lesions, and relieve joint symptoms.

🔬 Mechanism of Action

Secukinumab blocks IL-17A, preventing it from interacting with its receptor. This reduces inflammatory responses responsible for skin plaques, joint swelling, stiffness, and pain.

💊 Indications

Scapho 150 mg is indicated for:

• Moderate to Severe Plaque Psoriasis
• Psoriatic Arthritis (PsA)
• Ankylosing Spondylitis (AS)
• Non-radiographic Axial Spondyloarthritis (nr-axSpA)

📌 Key Features of Scapho 150 mg

• Strength: 150 mg
• Dosage Form: Pre-filled syringe or auto-injector solution for subcutaneous injection
• Therapeutic Class: IL-17A Inhibitor / Biologic Immunotherapy
• Administration: Subcutaneous injection as per prescribed dosing schedule
• Maintenance Dose: Typically administered monthly after initial loading doses (as directed by a specialist)

⚕️ Benefits of Secukinumab

• Rapid reduction in psoriasis plaques
• Improvement in joint pain and stiffness
• Targeted biologic therapy
• Convenient self-administration option (if prescribed)

⚠️ Precautions

• Increased risk of infections
• Tuberculosis screening recommended before starting therapy
• Avoid live vaccines during treatment
• Use under rheumatologist or dermatologist supervision

Scapho 150 mg (Secukinumab Injection) is an advanced biologic treatment designed to provide long-term control of autoimmune inflammatory conditions, improving skin clearance, joint mobility, and overall quality of life when used under specialist care.